Logo do repositório
 
Publicação

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors

2022-12-01Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorTorrente, María
dc.contributor.authorBlanco, Mariola
dc.contributor.authorFranco, Fabio
dc.contributor.authorGaritaonaindia, Yago
dc.contributor.authorCalvo, Virginia
dc.contributor.authorCollazo-Lorduy, Ana
dc.contributor.authorGutiérrez, Lourdes
dc.contributor.authorSánchez, Juan Cristóbal
dc.contributor.authorGonzález-del-Alba, Aranzazu
dc.contributor.authorHernández, Roberto
dc.contributor.authorMéndez, Miriam
dc.contributor.authorCantos, Blanca
dc.contributor.authorNúñez, Beatriz
dc.contributor.authorSousa, Pedro A. C.
dc.contributor.authorProvencio, Mariano
dc.contributor.institutionDEE - Departamento de Engenharia Electrotécnica e de Computadores
dc.contributor.pblFrontiers Media
dc.date.accessioned2023-01-27T22:20:13Z
dc.date.available2023-01-27T22:20:13Z
dc.date.issued2022-12-01
dc.descriptionFunding Information: This article is part of the CLARIFY project, supported by the European Union Horizon 2020 Research and Innovation Program under grant agreement number 875160. Publisher Copyright: Copyright © 2022 Torrente, Blanco, Franco, Garitaonaindia, Calvo, Collazo-Lorduy, Gutiérrez, Sánchez, González-del-Alba, Hernández, Méndez, Cantos, Núñez, Sousa and Provencio.
dc.description.abstractBackground: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, despite their excellent therapeutic effect, these medications typically result in a broad spectrum of toxicity reactions. Immune-related cardiotoxicity is uncommon but can be potentially fatal, and its true incidence is underestimated in clinical trials. The aim of this study is to assess the incidence and identify risk factors for developing a cardiac event in patients treated with ICIs. Methods: We conducted a single-institution retrospective study, including patients treated with ICIs in our center. The main outcomes were cardiac events (CE) and cardiovascular death. Results: A total of 378 patients were analyzed. The incidence of CE was 16.7%, during a median follow-up of 50.5 months. The multivariable analysis showed that age, a history of arrhythmia or ischemic heart disease, and prior immune-related adverse events were significantly associated with CE. Conclusion: CE during ICI treatment are more common than currently appreciated. A complete initial cardiovascular evaluation is recommended, especially in high-risk patients, being necessary a multidisciplinary approach of a specialized cardio-oncology team.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent10
dc.format.extent690474
dc.identifier.doi10.3389/fcvm.2022.1062858
dc.identifier.issn2297-055X
dc.identifier.otherPURE: 51567363
dc.identifier.otherPURE UUID: da120b5f-0796-43e2-8374-17a243d0e206
dc.identifier.otherScopus: 85144019634
dc.identifier.otherWOS: 000898362900001
dc.identifier.otherPubMed: 36531707
dc.identifier.otherPubMedCentral: PMC9751318
dc.identifier.urihttp://hdl.handle.net/10362/148293
dc.identifier.urlhttps://www.scopus.com/pages/publications/85144019634
dc.language.isoeng
dc.peerreviewedyes
dc.subjectcardiotoxicity
dc.subjectcardiovascular event
dc.subjectimmune checkpoint inhibitors
dc.subjectmyocarditis
dc.subjectrisk factors
dc.subjectCardiology and Cardiovascular Medicine
dc.subjectSDG 3 - Good Health and Well-being
dc.titleAssessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitorsen
dc.typejournal article
degois.publication.titleFrontiers in Cardiovascular Medicine
degois.publication.volume9
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Assessing_the_risk_of_cardiovascular_events_in_patients_receiving_immune_checkpoint_inhibitors.pdf
Tamanho:
674.29 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

Home collection (FCT)